研究表明激素治疗长期存在风险
Study of hormone therapy shows some risks persistCHICAGO (Reuters) - A follow-up analysis of women taking hormone replacement therapy found that their heightened risk of breast cancer persisted even after they stopped taking the drug combination, researchers said on Tuesday.
芝加哥（路透社）——周二研究人员声称对一组服用激素替代治疗的妇女进行随访分析后发现其乳腺癌的高危性即使在停止服用后依然持续存在。
The Women's Health Initiative study was halted prematurely in 2002 because of a 24 percent higher risk of breast cancer associated with the combination therapy of estrogen and progestin. Progestin is used to offset the heightened risk of uterine cancer from taking estrogen.
2002年妇女健康起始研究被贸然停止，因为乳腺癌的24%的高危性与雌激素和孕激素的联合治疗密切相关。服用孕激素来抵消服用雌激素的妇女得子宫癌的危险性。
The original study found women taking the combination of hormones also doubled their risk of blood clots, and raised their risks of stroke and heart attack.
原始研究发现联合服用这两种激素的妇女也使得血栓的风险加倍，得中风和心梗的风险升高。
The overriding conclusion from the two Women's Health Initiative trials involving 27,347 post-menopausal women, aged 50 to 79, was that the overall risks of long-term use of hormone therapy outweighed the benefits.
妇女健康起始研究对27，347位年龄在50-79岁的绝经后妇女进行了两次试验，其主要结论：长期服用激素治疗弊大于利。
The 2-1/2-year follow-up analysis, led by Gerardo Heiss of the University of North Carolina and published in the Journal of the American Medical Association, assessed through 2005 the health of 15,730 women who took the combination of hormones.北卡罗来纳大学的Gerardo Heiss于2005年对15，730位联合服用雌孕激素的健康妇女进行了两年半的随访分析，其结果刊登在美国医学会会刊的杂志上。
After the women stopped therapy, their heightened risk of breast cancer remained roughly the same. But their risks of heart attack, blood clots and stroke receded quickly back to levels among women who had not taken hormone therapy.
停止治疗后，这些妇女患乳腺癌的高风险性大致与服用时一致。但是他们患心脏病，血栓和中风的风险很快回到那些未服用激素治疗的女性水平。
The ancillary benefits of combination hormone therapy -- lower risks of colon cancer and bone fractures -- also disappeared after therapy was stopped.
联合雌孕激素治疗的其他好处在于可以降低结肠癌和骨折的风险，停止治疗后此效应也随之消失。
\"The good news is that after women stop taking combination hormone therapy, their risk of heart disease appears to decrease,\" said Dr. Elizabeth Nabel, director of the National Heart, Lung, and Blood Institute, part of the U.S. National Institutes of Health that sponsored the original WHI study.
美国国立健康研究院的国立心肺血液研究院资助初始WHI研究，其院长Dr. Elizabeth Nabel说：“妇女停止服用雌孕激素治疗后，患心脏病的风险下降。”
\"However, these findings also indicate that women who take estrogen plus progestin continue to be at increased risk of breast cancer, even years after stopping therapy,\" Nabel said in a statement.
Nabel在发言中说：“然而，这些结果也表明服用雌激素和孕激素的妇女患乳腺癌的风险持续存在，即便在停止服用数年后。”
EFFECTS LINGER
效应持久不衰
\"The hormones' effects on breast cancer appear to linger,\" said Dr. Leslie Ford of the Division of Cancer Prevention at the NIH's National Cancer Institute. \"These findings reinforce the importance of women getting regular breast exams and mammograms, even after they stop hormone therapy.\"
NIH国立癌症研究院的癌症预防部的Dr. Leslie Ford说：“激素对乳腺癌的效应持久不衰。这些结果强化了女性做常规乳腺检查和乳腺钼靶摄片的重要性，即便在停止服用激素后也是必须的。”
The WHI study, designed to examine whether hormone therapy prevented heart attacks, has been closely scrutinized. The surprise findings triggered a steep drop in the use of combination therapy and recommendations to employ lower dosages of the hormones for the shortest possible time.
旨在探讨激素疗法是否能防止心脏病发作的WHI研究，一直被人们密切关注着。研究结果出人意料，表明了使用两种激素综合疗法的害处，使激素替代疗法的应用数量急剧下降。我们建议在短时间内低剂量应用激素。
In a news conference organized by drug maker Wyeth, the company, which is the leading maker of hormone replacement therapy, said the follow-up analysis was likely to add to the confusion for women faced with the decision about what to do about disruptive symptoms of menopause such as hot flashes, night sweats and vaginal atrophy.
主要制造激素联合治疗的制药商Wyeth公司在其组织的新闻发布会上声称随访分析可能给那些面临绝经症状如潮红，盗汗和阴道萎缩等症状的妇女增添了困惑。
For one thing, the company said, the women in the study tended to be older -- average age 63, compared to the early 50s for most women at the onset of menopause -- and many did not have menopausal symptoms when they began taking the therapy.
一方面公司说研究中的妇女年龄比较大——平均63岁，而大多数刚绝经的妇女不过50岁。他们在刚开始服用激素治疗的时候并没有绝经症状。
\"In recent years there has been reanalysis of WHI findings that have shown that the increased risks associated with the older women, as described in this study, were not consistently shared by the younger women who participated in the study,\" said Wyeth's chief medical officer Gary Stiles.
Wyeth公司主席Gary Stiles说：“近年来对WHI结果重新分析发现正如研究中所描述的，风险的增加在年龄大的妇女中存在，但在参与研究的年轻妇女中并不一致。”
“妇女停止服用雌孕激素治疗后，患心脏病的风险下降。然而这些结果也即便停用雌孕激素数年后，这些妇女患乳腺癌的风险也持续存在。”
以上结果显示，还是不用激素为好!
页:
[1]